99% Pure | USA Finished | Multi Dose Trinity-X™ is a cutting-edge tri-agonist peptide that is transforming the field of metabolic research. Engineered to simultaneously activate three key metabolic receptors—GLP-1, GIP, and GCGR (glucagon)—this multifunctional compound offers a comprehensive and synergistic approach to modulating appetite signaling, enhancing insulin function, and accelerating fat metabolism pathways in research settings.

99% Pure | USA Finished | Multi Dose MOTS-c peptide is a 16–amino-acid mitochondrial-derived signaling peptide used in preclinical models to probe energy-metabolism, insulin sensitivity, and cellular stress responses. In cell culture and rodent assays, MOTS-c enhances glucose uptake, modulates AMPK pathways, and supports resilience under metabolic stress. Each 10 mg vial is USA-manufactured, HPLC-verified to ≥ 99% purity, endotoxin-screened (< 0.1 EU/mg), and formulated for laboratory research.

99% Pure | USA Finish | Multi Dose Tesamorelin is a lab-grade GHRH analog designed to deliver clean, repeatable growth-hormone (GH) pulses in cell-based and rodent models. By mimicking your body’s natural GHRH but resisting rapid breakdown, Tesamorelin injections enable precise studies of fat-metabolism, IGF-1 activation, and endocrine-feedback loops. Each 10 mg vial is USA-manufactured under ISO standards, HPLC-verified to ≥ 99% purity, and endotoxin-screened (< 0.1 EU/mg).

99% Pure | USA Finished| Multi Dose BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring gastric-juice protein, prized in laboratory models for its potent tissue-repair and angiogenic signaling. In preclinical assays, BPC-157 accelerates wound closure, supports blood-vessel formation, and protects the gut mucosa—without any systemic growth-hormone activity. Each 10 mg vial is produced under ISO-certified conditions, verified ≥99% purity by HPLC, screened for endotoxin (<0.1 EU/mg), and shipped with a Certificate of Analysis for your protocols.

99% Pure | USA Finished | Multi Dose NAD⁺ (Nicotinamide Adenine Dinucleotide) is a central coenzyme studied for its role in cellular energy production, mitochondrial signaling, DNA repair pathways, and age-related metabolic decline. Injectable NAD⁺ is commonly used in research to model rapid NAD⁺ replenishment and evaluate downstream effects on ATP activity, oxidative stress markers, and longevity-linked mechanisms. Real Peptides NAD injection is USA-made, third-party lab tested, and purity-verified for consistent, reproducible study outcomes.

99% Pure | USA Made | Multi Dose The KLOW Peptide Blend is a powerful, research-backed peptide blend that synergistically combines GHK-Cu, BPC-157, TB-500, and KPV into a single, high-potency formula. Each vial provides a precise blend optimized for studies involving tissue repair, accelerated regeneration, anti-inflammatory signaling, and enhanced cellular recovery. Lab-produced, USA-made, and certified ≥99% purity, KLOW streamlines peptide research by providing consistent, reliable ratios in every dose

99% Pure | USA Finished | Multi Dose Tesofensine capsules each contain 500 µg of high-purity Tesofensine—a triple-reuptake inhibitor peptide used to model appetite control, energy-burn, and metabolic signaling in cell cultures and animal studies. Supplied in a 100-count bottle, these ready-to-use tablets eliminate the need for micro-weighing or powder handling. USA-manufactured under GMP, HPLC-verified to ≥ 99% purity, and formulated with only microcrystalline cellulose, Tesofensine capsules make it easy to run oral-dosing protocols with confidence.

June 17, 2026

VIP vs Vasoactive Intestinal Peptide — Same Molecule

Q: Tesamorelin 10mg

99% Pure | USA Finish | Multi Dose Tesamorelin is a lab-grade GHRH analog designed to deliver clean, repeatable growth-hormone (GH) pulses in cell-based and rodent models. By mimicking your body’s natural GHRH but resisting rapid breakdown, Tesamorelin injections enable precise studies of fat-metabolism, IGF-1 activation, and endocrine-feedback loops. Each 10 mg vial is USA-manufactured under ISO standards, HPLC-verified to ≥ 99% purity, and endotoxin-screened (< 0.1 EU/mg).

Q: Wolverine Peptide Stack

99% Pure | USA Made | Multi Dose The Ultimate Research Duo (BPC-157 + TB-500). The Wolverine Stack pairs two of the most potent research peptides—BPC-157 and TB-500—for cutting-edge studies on accelerated repair, tissue regeneration, and systemic recovery. Revered in the scientific community, this stack mimics the legendary regenerative potential that inspired its name. Now in stock and available at Real Peptides, this synergistic combo brings together the most studied tissue-repairing compounds into one powerfully compliant research stack.

Q: BPC-157 10mg

99% Pure | USA Finished| Multi Dose BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring gastric-juice protein, prized in laboratory models for its potent tissue-repair and angiogenic signaling. In preclinical assays, BPC-157 accelerates wound closure, supports blood-vessel formation, and protects the gut mucosa—without any systemic growth-hormone activity. Each 10 mg vial is produced under ISO-certified conditions, verified ≥99% purity by HPLC, screened for endotoxin (<0.1 EU/mg), and shipped with a Certificate of Analysis for your protocols.

Q: NAD+

99% Pure | USA Finished | Multi Dose NAD⁺ (Nicotinamide Adenine Dinucleotide) is a central coenzyme studied for its role in cellular energy production, mitochondrial signaling, DNA repair pathways, and age-related metabolic decline. Injectable NAD⁺ is commonly used in research to model rapid NAD⁺ replenishment and evaluate downstream effects on ATP activity, oxidative stress markers, and longevity-linked mechanisms. Real Peptides NAD injection is USA-made, third-party lab tested, and purity-verified for consistent, reproducible study outcomes.

Q: KLOW

99% Pure | USA Made | Multi Dose The KLOW Peptide Blend is a powerful, research-backed peptide blend that synergistically combines GHK-Cu, BPC-157, TB-500, and KPV into a single, high-potency formula. Each vial provides a precise blend optimized for studies involving tissue repair, accelerated regeneration, anti-inflammatory signaling, and enhanced cellular recovery. Lab-produced, USA-made, and certified ≥99% purity, KLOW streamlines peptide research by providing consistent, reliable ratios in every dose

Q: Bacteriostatic Reconstitution Water (BAC)

99% Pure | USA Made | Multi Dose Real Peptides BAC Reconstitution Water is a sterile bacteriostatic mixing solution designed for reconstituting peptides. Each vial contains USP-grade water with 0.9% benzyl alcohol, a preservative that prevents bacterial growth and allows for multi-use over time. We have 3 size options; 2ml, 3ml & 10ml. This reconstitution solution is ideal for peptide storage, reconstitution, and safe lab handling. It is manufactured under ISO-certified clean room conditions and sealed for purity.

Q: Tesofensine Tablets

99% Pure | USA Finished | Multi Dose Tesofensine capsules each contain 500 µg of high-purity Tesofensine—a triple-reuptake inhibitor peptide used to model appetite control, energy-burn, and metabolic signaling in cell cultures and animal studies. Supplied in a 100-count bottle, these ready-to-use tablets eliminate the need for micro-weighing or powder handling. USA-manufactured under GMP, HPLC-verified to ≥ 99% purity, and formulated with only microcrystalline cellulose, Tesofensine capsules make it easy to run oral-dosing protocols with confidence.

Q: TB-500 (Thymosin Beta-4)

99% Pure | USA Finish | Multi Dose TB500 (Thymosin Beta-4) is a synthetic 43-amino-acid peptide fragment used in preclinical models to explore tissue repair, cell migration, and inflammation resolution. In cell-culture wound-closure assays and rodent injury models, TB-500 accelerates fibroblast migration, modulates cytokine profiles, and supports angiogenic signaling. Each 10 mg vial is USA-manufactured, HPLC-verified to ≥ 99% purity, endotoxin-screened (< 0.1 EU/mg), and formulated for laboratory research.

June 17, 2026

VIP vs Vasoactive Intestinal Peptide — Same Molecule

VIP and vasoactive intestinal peptide aren't two different things. They're the exact same molecule. VIP is just the acronym researchers use because typing 'vasoactive intestinal peptide' every time would take forever. The confusion comes from seeing both names in literature, supplement labels, and research peptide catalogs without realizing they're identical. The peptide was first isolated from porcine duodenum in 1970 by Said and Mutt at the Karolinska Institute. The name 'vasoactive intestinal peptide' reflects its original discovery site and its ability to dilate blood vessels, but the molecule functions far beyond the gut.

Our team works with researchers who order VIP for studies ranging from neuroinflammation to circadian rhythm modulation. The question comes up constantly. 'Is VIP different from vasoactive intestinal peptide?'. And the answer is always no.

What's the difference between VIP and vasoactive intestinal peptide?

There is no difference. VIP is the acronym for vasoactive intestinal peptide. Both refer to the same 28-amino-acid neuropeptide that acts as a neurotransmitter, hormone, and immune modulator throughout the body. The molecule was named for its discovery site in the intestine and its vasodilatory effects, but it functions in the brain, lungs, and immune system as well. The acronym VIP is used universally in research literature because it's faster to write.

Why the Name 'Vasoactive Intestinal Peptide' Is Misleading

The name 'vasoactive intestinal peptide' makes it sound like this molecule only affects blood vessels in the gut. Which is technically where it was first isolated, but functionally incomplete. VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily, and it's distributed throughout the central nervous system, peripheral nervous system, and immune tissues. The highest concentrations are found in the hypothalamus, cerebral cortex, and gut. But VIP receptors (VPAC1 and VPAC2) exist on neurons, immune cells, smooth muscle, and endothelial tissue across the entire body.

The 'vasoactive' part refers to its ability to relax vascular smooth muscle through nitric oxide (NO) and cyclic AMP pathways, causing vasodilation. The 'intestinal' part reflects its discovery in the duodenum during experiments on gastrointestinal motility. Said and Mutt were studying secretin analogs when they isolated VIP from pig intestinal extracts. The 'peptide' part is straightforward. It's a short chain of amino acids (28 residues, to be exact).

But here's what the name doesn't tell you: VIP modulates T-cell differentiation, suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-12), regulates circadian rhythm through the suprachiasmatic nucleus, and acts as a neuroprotective agent in models of Alzheimer's and Parkinson's disease. Calling it an 'intestinal' peptide undersells its systemic role. In our experience guiding researchers through peptide selection, VIP is more accurately described as a pleiotropic signaling molecule with neuroimmune, circadian, and metabolic functions. The gut connection is real, but it's one function among many.

VIP Receptor Types and Tissue Distribution

VIP (vasoactive intestinal peptide) exerts its effects by binding to two G-protein-coupled receptors: VPAC1 and VPAC2. Both receptors have equal affinity for VIP and another related peptide called PACAP (pituitary adenylate cyclase-activating polypeptide), but their tissue distribution and downstream signaling differ meaningfully. VPAC1 is expressed broadly across the brain, lungs, liver, intestine, and immune cells. It's the dominant receptor in T-lymphocytes and macrophages, which is why VIP has such potent immunomodulatory effects. VPAC2 is concentrated in the suprachiasmatic nucleus (the brain's circadian clock), smooth muscle, and pancreatic beta cells.

When VIP binds to either receptor, it activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP). This triggers downstream signaling cascades that regulate gene transcription, ion channel activity, and inflammatory mediator release. In neurons, elevated cAMP enhances synaptic plasticity and neuroprotection. In immune cells, it shifts the balance from Th1 (pro-inflammatory) to Th2 (regulatory) responses, suppressing cytokines like IL-12 and TNF-α while upregulating anti-inflammatory IL-10.

The receptor distribution explains why VIP has such diverse effects: VPAC1 dominance in immune tissue makes it a research target for autoimmune and inflammatory conditions, while VPAC2 concentration in the suprachiasmatic nucleus ties it to circadian rhythm regulation and sleep-wake cycle stability. Researchers working with Real Peptides VIP formulations typically target one pathway or the other depending on study design. Immune modulation studies focus on VPAC1-rich tissues, while circadian or metabolic studies target VPAC2-dense regions.

When You'd See 'VIP' vs 'Vasoactive Intestinal Peptide' Written Out

In research literature, you'll see the full name 'vasoactive intestinal peptide' written out exactly once. In the first mention of the molecule in a paper's abstract or introduction, followed immediately by '(VIP)' in parentheses. Every subsequent reference uses the acronym. This is standard scientific writing convention: define the acronym on first use, then use the acronym for the rest of the document. You'll almost never see 'vasoactive intestinal peptide' spelled out repeatedly unless the author is unfamiliar with standard nomenclature or the publication has unusual style rules.

On supplement labels or research peptide supplier sites, you might see both 'VIP' and 'Vasoactive Intestinal Peptide' used interchangeably in product descriptions. Usually because the full name is more SEO-friendly and helps customers who are searching for the spelled-out term rather than the acronym. At Real Peptides, we list both the acronym and the full chemical name in catalog entries to avoid confusion, but the product itself is identical regardless of which name is used. The peptide sequence is the same, the purity standards are the same, and the storage requirements are the same.

In clinical or pharmacological contexts, you'll sometimes see 'VIP' capitalized without periods (VIP, not V.I.P.) to distinguish it from 'very important person'. But this is context-dependent. If you're reading a paper on neuropeptides, 'VIP' unambiguously means vasoactive intestinal peptide. If you're reading a hospitality industry report, it probably doesn't.

VIP vs Vasoactive Intestinal Peptide: Research Grade Comparison

Feature	VIP (Acronym Form)	Vasoactive Intestinal Peptide (Full Name)	Bottom Line
Chemical Identity	28-amino-acid neuropeptide from secretin superfamily	Identical. Same 28-amino-acid sequence	No structural difference. Same molecule
Amino Acid Sequence	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Identical sequence. Abbreviation doesn't change structure	The name is cosmetic. The peptide is the same
Receptor Targets	VPAC1, VPAC2	VPAC1, VPAC2	Both names refer to the same receptor-binding molecule
Tissue Distribution	CNS, PNS, gut, immune cells, vasculature	Identical distribution. Found in same tissues	Location independent of naming convention
Primary Functions	Vasodilation, immune modulation, circadian regulation	Same functions. Neuroprotection, anti-inflammatory, GI motility	Functional profile unchanged by nomenclature
Research Applications	Neuroinflammation, autoimmune models, circadian studies	Identical applications. Same experimental uses	Literature uses 'VIP' almost exclusively

Key Takeaways

VIP and vasoactive intestinal peptide are the exact same 28-amino-acid neuropeptide. VIP is simply the acronym used in research literature after the first mention.
The molecule was discovered in 1970 in porcine duodenum by Said and Mutt at the Karolinska Institute, which is why it's named 'intestinal' despite functioning systemically.
VIP binds to two G-protein-coupled receptors (VPAC1 and VPAC2) that are distributed across the brain, immune system, gut, and smooth muscle. Not just the intestine.
In scientific writing, the full name 'vasoactive intestinal peptide' appears once at first mention, followed by '(VIP)'. Every subsequent reference uses the acronym.
Research-grade VIP from suppliers like Real Peptides is synthesized to the same 28-amino-acid sequence regardless of whether the product label uses the acronym or the full name.

What If: VIP vs Vasoactive Intestinal Peptide Scenarios

What If I See a Product Labeled 'VIP Peptide' — Is That Different from 'Vasoactive Intestinal Peptide'?

No. It's the same molecule. 'VIP peptide' is redundant phrasing (VIP already stands for 'vasoactive intestinal peptide'), but suppliers sometimes write it that way for clarity or SEO purposes. The peptide sequence, purity, and function are identical whether the label says 'VIP', 'VIP peptide', or 'Vasoactive Intestinal Peptide'. What matters is the Certificate of Analysis (CoA) showing purity ≥98% and correct mass spectrometry confirmation. Not the product name.

What If a Research Paper Uses Only the Acronym 'VIP' Without Defining It — How Do I Know It's Vasoactive Intestinal Peptide?

Context clues tell you immediately. If the paper discusses neuropeptides, immune modulation, circadian rhythms, or VPAC receptors, 'VIP' definitively means vasoactive intestinal peptide. If the paper is outside biomedical research (business, hospitality, event planning), 'VIP' likely means something else. In our experience reviewing thousands of peptide research protocols, 'VIP' in a biological sciences context has never referred to anything other than vasoactive intestinal peptide.

What If I'm Ordering Research Peptides and the Catalog Lists Both 'VIP' and 'Vasoactive Intestinal Peptide' as Separate Products?

That would be an error. Contact the supplier for clarification. No legitimate peptide supplier sells 'VIP' and 'vasoactive intestinal peptide' as distinct products because they're the same molecule. If a catalog lists them separately with different CAS numbers, SKU codes, or pricing, one entry is mislabeled. At Real Peptides, we use a single SKU for VIP with both the acronym and full name in the product description to avoid this exact confusion.

The Blunt Truth About VIP vs Vasoactive Intestinal Peptide

Here's the honest answer: this isn't a 'versus' comparison. It's the same peptide with two names. The confusion exists entirely because people see 'VIP' written in shorthand on research protocols or supplement labels and assume it's a different molecule from 'vasoactive intestinal peptide' spelled out in full. It's not. The acronym was adopted decades ago because writing 'vasoactive intestinal peptide' repeatedly in a 10-page research paper wastes time and space. Every credible source. PubChem, UniProt, the IUPHAR/BPS Guide to Pharmacology. Confirms that VIP and vasoactive intestinal peptide share the same CAS number (37221-79-7), the same amino acid sequence, and the same biological function. If you're choosing between two products labeled differently, you're not choosing between two peptides. You're choosing between two suppliers selling the same thing.

The only real difference is the name on the label. The molecule inside is identical. If a supplier tells you otherwise, find a different supplier. At Real Peptides, every batch of VIP (or 'vasoactive intestinal peptide' if you prefer the full name) is synthesized to the same 28-amino-acid sequence with ≥98% purity verified by HPLC and mass spectrometry. Because there's only one correct sequence, and it doesn't change based on what you call it.

VIP and vasoactive intestinal peptide are the same molecule. The acronym is standard shorthand in research, and the full name is what you'll see in formal introductions or product descriptions. The peptide's function, receptor targets, and amino acid sequence are identical regardless of which name is used. If you're ordering research-grade peptides, confirm purity with a Certificate of Analysis and verify the sequence matches the 28-amino-acid structure. The label can say 'VIP', 'vasoactive intestinal peptide', or 'VIP peptide', but the molecule inside should always be the same.

Frequently Asked Questions

Is VIP the same thing as vasoactive intestinal peptide?▼

Yes — VIP is the acronym for vasoactive intestinal peptide. They refer to the exact same 28-amino-acid neuropeptide discovered in 1970. The acronym is used universally in research literature because it’s faster to write than the full name.

Why is it called ‘vasoactive intestinal peptide’ if it works outside the intestine?▼

The name reflects its discovery site in porcine duodenum and its ability to dilate blood vessels (vasodilation), but the molecule functions systemically — in the brain, lungs, immune system, and smooth muscle. The ‘intestinal’ label is historically accurate but functionally incomplete.

Can I use VIP and vasoactive intestinal peptide interchangeably in research documentation?▼

Yes, but follow standard scientific writing convention: write ‘vasoactive intestinal peptide (VIP)’ on first mention, then use ‘VIP’ for all subsequent references. Writing the full name repeatedly is considered poor style in research literature.

What receptors does VIP bind to, and how does that relate to its full name?▼

VIP binds to VPAC1 and VPAC2 receptors (vasoactive intestinal peptide receptors) throughout the body. Both names — VIP and vasoactive intestinal peptide — refer to the same ligand that activates these G-protein-coupled receptors to increase intracellular cyclic AMP.

Are there any structural differences between products labeled VIP vs vasoactive intestinal peptide?▼

No — the amino acid sequence is identical regardless of labeling. Both refer to the same 28-residue peptide (sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN). What matters is purity verification via HPLC and mass spectrometry, not the product name.

How do I know if a research paper is referring to vasoactive intestinal peptide when it only says VIP?▼

Context makes it clear — if the paper discusses neuropeptides, VPAC receptors, immune modulation, or circadian rhythms, ‘VIP’ definitively means vasoactive intestinal peptide. In biomedical research, VIP has no other meaning.

What is the CAS number for VIP, and does it differ from vasoactive intestinal peptide?▼

The CAS number is 37221-79-7 for both — because they’re the same molecule. PubChem, UniProt, and the IUPHAR/BPS Guide to Pharmacology all list VIP and vasoactive intestinal peptide under the same registry number.

Why do some peptide suppliers list both VIP and vasoactive intestinal peptide in their catalogs?▼

Usually for SEO or customer clarity — some researchers search for the acronym, others for the full name. Legitimate suppliers sell the same product under both names. If a catalog lists them as separate products with different SKUs or pricing, one is mislabeled.

Does VIP work differently depending on whether it is labeled as an acronym or spelled out?▼

No — the biological function, receptor affinity, and downstream signaling are identical. The name on the label doesn’t change the peptide’s mechanism of action, tissue distribution, or pharmacokinetics.

What should I look for in a Certificate of Analysis when ordering VIP or vasoactive intestinal peptide?▼

Verify purity ≥98% by HPLC, confirm the molecular weight matches 3326.77 Da (the theoretical mass of the 28-amino-acid sequence), and check that the amino acid analysis matches the expected sequence. The CoA should be identical whether the product is labeled VIP or vasoactive intestinal peptide.